A Study to Evaluate the Efficacy and Safety of AD-208

• Status: Recruiting
• Trial end date: 2022-04-22
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-208.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Addpharma Inc.

Criteria

Inclusion Criteria:

• Male patients aged 18-50 years, inclusive

• Patients who meet the appropriate criteria according to the classification of hair loss

• Signed informed consent

Exclusion Criteria:

• Patients with hair loss disorders other than androgenetic alopecia

• Other exclusions applied